Experts: FDA's Made 'Laudable' Progress, But Efforts Fall Short
This article was originally published in Scrip
Executive Summary
While the FDA has made "extensive, transformative and laudable" progress since a scathing 2007 report by a subcommittee of the agency's Science Board condemned regulators for failing to fulfill their mission because of a weak scientific base and lack of scientific workforce, the same panel of outside expert advisers in a new analysis, unveiled on Sept. 18, identified a number of areas in which improvements continue to be needed.